P2RY12 and migraine disorder: Overall, in the present review, the favorable effects of antiplatelet medication of the P2Y12 inhibitor for migraine, the nearly parallel (95%) MHA response to subsequent PFO closure, and the lower rate of new-onset migraine after ASDC all suggest a platelet-mediated or platelet-activated mechanism of migraine.